News

News 2017-11-19T23:06:00+00:00

Autolus announces update on AUTO4 and AUTO5 programmes

LONDON, 3 December 2018: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL) (“Autolus”), announced that the first patient has been dosed in its Phase 1/2 LibrA T1 clinical trial of AUTO4, a developmental therapy for the treatment of relapsed or refractory TRBC1-positive peripheral T cell lymphoma (PTCL). In addition, [...]

December 3rd, 2018|

Autolus presents initial AUTO3 clinical data at ASH

LONDON, 3 December 2018: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes that its portfolio company, Autolus Therapeutics plc (NASDAQ: AUTL) (“Autolus”), announced updated results from its ongoing AUTO3 Phase 1/2 clinical trials in paediatric acute lymphoblastic leukemia (AMELIA trial) and diffuse large B cell lymphoma (ALEXANDER trial), presented at the 60th American Society of Hematology (ASH) [...]

December 3rd, 2018|

Pharmaxis releases positive results of Phase 1 clinical trial for second LOXL2 inhibitor compound

LONDON, 15 November 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, has announced positive results from the Phase 1 clinical trial for the second of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat [...]

November 15th, 2018|

Autolus Therapeutics to Present New Data at the ASH Annual Meeting

LONDON, 2 November 2018: Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation notes one of its Group Businesses, Autolus Therapeutics plc (NASDAQ: AUTL) (Autolus), will present one oral and two poster presentations related to its AUTO3 and AUTO5 programs at the 60th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 1-4, 2018 in [...]

November 2nd, 2018|

Aura Biosciences reports positive Phase 1b/2 clinical data for AU-011

Multiple doses of AU-011 are well tolerated, with vision preservation observed at 12 to 18 months All Patients met preliminary efficacy endpoint to date with evidence of biological activity Aura plans to initiate a pivotal Phase 3 clinical study LONDON, 30 October 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that Aura [...]

October 30th, 2018|

Pharmaxis releases positive results of Phase 1 clinical trial for LOXL2 inhibitor compound

LONDON, 11 October 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that its Group Business, Pharmaxis Ltd (ASX: PXS), an Australian pharmaceutical research company focused on inflammation and fibrosis, today announced positive results from the Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed [...]

October 11th, 2018|

Update on LogicBio proposed initial public offering in the United States

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 10 October 2018 Arix Bioscience plc (LSE:ARIX) ("Arix"), a global healthcare and life science company supporting medical innovation, today notes that LogicBio Therapeutics Inc.(“LogicBio”) has filed an amended registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering [...]

October 10th, 2018|

Co-leads $58 million Series A investment round for VelosBio

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014   Arix co-leads a $58 million Series A investment in new Group Business, VelosBio Inc., bringing core portfolio[1] to 15 companies Arix commits $11 million (£8.4 million)[2] for 11.2% ownership stake Co-investment with strategic partner Takeda and leading venture capital investors Arix further strengthens position in oncology; investment in VelosBio [...]

October 1st, 2018|

LogicBio files registration for proposed IPO in the US

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF THE EU MARKET ABUSE REGULATION NO.596/2014 LONDON, 26 September 2018: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, announces that one of its Group Businesses, LogicBio Therapeutics Inc. (“LogicBio”), a genome editing company focused on developing medicines to durably treat rare diseases in patients [...]

September 26th, 2018|

Update on Iterum Therapeutics Phase 3 trials

LONDON, 18 September 2018: Arix Bioscience plc ("Arix") (LSE: ARIX), a global healthcare and life science company supporting medical innovation, is pleased to note that its Group Business, Iterum Therapeutics plc (“Iterum”) (Nasdaq: ITRM) has initiated the remaining two of three planned Phase 3 pivotal trials (SURE 2 and SURE 3) of IV and Oral Sulopenem in Complicated Urinary Tract and Complicated Intra-abdominal Infections. Iterum [...]

September 18th, 2018|